Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Myeloma
•
Hematology
What is your preferred dose and schedule for maintenance drugs post autoHCT for newly diagnosed multiple myeloma?
Related Questions
When, if ever, would you select a three-drug regimen instead of four-drug regimen in patients with newly diagnosed Multiple Myeloma?
Is there a role for CRS prophylaxis with tocilizumab during bispecific T cell engager initiation for myeloma?
How do you evaluate a patient with MGUS and peripheral neuropathy?
In a patient with history of recurrent VTE despite anticoagulation, would you consider lenalidomide as part of your initial myeloma regimen?
Under what circumstances is it okay to initiate treatment for suspected multiple myeloma without a bone marrow biopsy?
How would you approach management and monitoring of AL amyloidosis with isolated renal involvement?
How does one approach maintenance treatment in transplant ineligible patients with newly diagnosed multiple myeloma?
How do you approach the second-line treatment for a patient with high-risk myeloma relapse early post-autoHCT after Dara-RVD induction?
What is your re-immunization strategy after auto SCT for patients with myeloma on dara/len maintenance?
Should you consider thromboprophylaxis, even for low-dose lenalidomide maintenance, post-autologous transplantation?
